Erratum: Cessation of vascular endothelial growth factortargeted therapy in patients with metastatic renal cell carcinoma. (Cancer (2012) DOI: 10.1002/cncr.26666);Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: Feasibility and clinical outcome

Cancer

Volumn 118, Issue 13, 2012, Pages 3277-3282

  Sadeghi, Sarmad ^a   Albiges, Laurence ^b   Wood, Laura S ^a   Black, Shari L ^a   Gilligan, Timothy D ^a   Dreicer, Robert ^a   Garcia, Jorge A ^a   Escudier, Bernard J ^b   Rini, Brian I ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Expectant management; Observation; Renal cell carcinoma; Sunitinib; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; SORAFENIB; SUNITINIB; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DIARRHEA; DISEASE COURSE; DRUG COST; DRUG ERUPTION; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; FRANCE; HAND FOOT SYNDROME; HAZARD RATIO; HEART EJECTION FRACTION; HEART INFARCTION; HEMORRHOID; HUMAN; HYPERTENSION; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; KIDNEY SURGERY; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NAUSEA; NEPHRECTOMY; PANCREAS METASTASIS; PERIANAL ABSCESS; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROTEINURIA; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SIDE EFFECT; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; WATCHFUL WAITING;

EID: 84862582077     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27534     Document Type: Erratum

References (10)

1. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27: 3584-3590.
2. Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009; 27: 4462-4468.
3. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2008; 26: 3743-3748.
4. Johannsen M, Flörcken A, Bex A, et al. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol. 2009; 55: 1430-1438.
5. Albiges L, Oudard S, Negrier S, et al. Complete remission with TKI in renal cell carcinomas: Experience in 65 patients of the French Kidney Cancer Group. ASCO Meeting Abstracts. J Clin Oncol. 2010; 28 (15 suppl): (Abstract 4600).
6. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009; 27: 5794-5799.
7. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol. 2006; 24: 394-400. (Pubitemid 46630458)
8. Labianca R, Sobrero A, Isa L, et al. Italian Group for the Study of Gastrointestinal Cancer-GISCAD. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. Ann Oncol. 2011; 22: 1236-1242.
9. Mahon FX, Réa D, Guilhot J, et al. Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010; 11: 1029-1035.
10. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J,. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17: 2530-2540. (Pubitemid 29368255)